Medical device firm TriVascular Technologies has obtained approval from the US Food and Drug Administration (FDA) for its Ovation iX Abdominal Stent Graft System.
The new system features built-in procedural option that can be used to replace retrograde cannulation of the main body device, allowing to place the contralateral iliac stent graft.
It also features low profile 12-13F integrated sheath, which is designed to minimize vessel trauma and reduce procedural steps.
TriVascular Technologies CEO and president Christopher Chavez said: "The launch of the complete Ovation iX system supports our mission to improve and safely expand EVAR for all and serves as evidence of our commitment to deliver a strong pipeline of products.
"We believe the Ovation iX delivery system enhancements will complement the broad IFU of the Ovation system and further enable our physician partners to provide improved, on-label EVAR treatment to more patients."
TriVascular distributes Ovation Abdominal Stent Graft platform in around 35 countries.